-
AMLX Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Amylyx Pharmaceuticals (AMLX)
Company Profile
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 73.28 mm | 73.28 mm | 73.28 mm | 73.28 mm | 73.28 mm | 73.28 mm |
Cash burn (monthly) | 812.67 k | 5.22 mm | 25.22 mm | 22.30 mm | 13.86 mm | 7.92 mm |
Cash used (since last report) | 4.12 mm | 26.49 mm | 127.89 mm | 113.08 mm | 70.27 mm | 40.18 mm |
Cash remaining | 69.16 mm | 46.79 mm | -54.61 mm | -39.80 mm | 3.01 mm | 33.10 mm |
Runway (months of cash) | 85.1 | 9.0 | -2.2 | -1.8 | 0.2 | 4.2 |
13F holders | Current |
---|---|
Total holders | 126 |
Opened positions | 32 |
Closed positions | 21 |
Increased positions | 35 |
Reduced positions | 39 |
13F shares | Current |
---|---|
Total value | 184.78 bn |
Total shares | 58.95 mm |
Total puts | 410.60 k |
Total calls | 256.50 k |
Total put/call ratio | 1.6 |
Largest owners | Shares | Value |
---|---|---|
Perceptive Advisors | 6.77 mm | $25.61 bn |
TCG Crossover Management | 4.64 mm | $17.55 bn |
TCG Crossover GP II | 4.64 mm | $10.26 mm |
Vanguard | 2.69 mm | $10.18 bn |
BAC Bank of America | 2.43 mm | $9.17 bn |
Morningside Venture Investments | 2.31 mm | $43.30 mm |
BlackRock | 2.28 mm | $8.61 bn |
Panacea Innovation | 2.20 mm | $7.72 mm |
Almitas Capital | 2.03 mm | $7.68 bn |
Citadel Advisors | 1.97 mm | $7.45 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 Feb 25 | Gina Mazzariello | Common Stock | Sell | Dispose S | No | No | 3.153 | 4,169 | 13.14 k | 134,921 |
5 Feb 25 | Justin B. Klee | Common Stock | Option exercise | Acquire M | No | No | 1.57 | 36,310 | 57.01 k | 3,201,243 |
5 Feb 25 | Justin B. Klee | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.57 | 36,310 | 57.01 k | 0 |
3 Feb 25 | Justin B. Klee | Common Stock | Sell | Dispose S | No | No | 3.4672 | 11,855 | 41.10 k | 3,164,933 |
3 Feb 25 | Joshua B Cohen | Common Stock | Sell | Dispose S | No | No | 3.4687 | 11,851 | 41.11 k | 3,201,247 |
3 Feb 25 | Gina Mazzariello | Common Stock | Sell | Dispose S | No | No | 3.4908 | 3,678 | 12.84 k | 139,090 |